<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p249" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_249{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_249{left:306px;bottom:30px;}
#t3_249{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_249{left:346px;bottom:30px;}
#t5_249{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_249{left:517px;bottom:30px;}
#t7_249{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_249{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_249{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_249{left:1105px;bottom:27px;letter-spacing:0.25px;}
#tb_249{left:35px;bottom:777px;letter-spacing:0.04px;word-spacing:0.15px;}
#tc_249{left:35px;bottom:759px;letter-spacing:0.13px;word-spacing:-0.36px;}
#td_249{left:35px;bottom:739px;letter-spacing:0.09px;word-spacing:0.1px;}
#te_249{left:35px;bottom:720px;letter-spacing:-0.23px;word-spacing:1.63px;}
#tf_249{left:132px;bottom:720px;letter-spacing:0.16px;}
#tg_249{left:501px;bottom:720px;}
#th_249{left:35px;bottom:683px;letter-spacing:-0.09px;word-spacing:0.28px;}
#ti_249{left:35px;bottom:665px;letter-spacing:0.14px;word-spacing:-0.23px;}
#tj_249{left:35px;bottom:645px;letter-spacing:0.09px;word-spacing:0.1px;}
#tk_249{left:35px;bottom:625px;letter-spacing:0.16px;}
#tl_249{left:405px;bottom:625px;}
#tm_249{left:35px;bottom:589px;letter-spacing:0.03px;word-spacing:0.15px;}
#tn_249{left:35px;bottom:570px;letter-spacing:0.12px;word-spacing:0.07px;}
#to_249{left:35px;bottom:551px;letter-spacing:0.08px;word-spacing:0.11px;}
#tp_249{left:35px;bottom:531px;letter-spacing:-0.23px;word-spacing:1.63px;}
#tq_249{left:132px;bottom:531px;letter-spacing:0.16px;}
#tr_249{left:501px;bottom:531px;}
#ts_249{left:35px;bottom:495px;letter-spacing:0.09px;word-spacing:0.09px;}
#tt_249{left:35px;bottom:476px;}
#tu_249{left:35px;bottom:457px;letter-spacing:0.2px;}
#tv_249{left:79px;bottom:457px;}
#tw_249{left:35px;bottom:420px;letter-spacing:0.05px;word-spacing:-0.15px;}
#tx_249{left:35px;bottom:401px;letter-spacing:0.1px;word-spacing:0.09px;}
#ty_249{left:35px;bottom:382px;letter-spacing:0.08px;word-spacing:0.11px;}
#tz_249{left:35px;bottom:363px;letter-spacing:0.08px;word-spacing:0.11px;}
#t10_249{left:35px;bottom:343px;letter-spacing:0.16px;}
#t11_249{left:405px;bottom:343px;}
#t12_249{left:35px;bottom:306px;letter-spacing:0.02px;word-spacing:0.16px;}
#t13_249{left:35px;bottom:288px;letter-spacing:0.11px;word-spacing:0.08px;}
#t14_249{left:35px;bottom:269px;letter-spacing:0.01px;word-spacing:0.18px;}
#t15_249{left:35px;bottom:249px;letter-spacing:0.15px;word-spacing:0.05px;}
#t16_249{left:35px;bottom:229px;letter-spacing:-0.07px;word-spacing:0.25px;}
#t17_249{left:180px;bottom:229px;letter-spacing:0.16px;}
#t18_249{left:549px;bottom:229px;}
#t19_249{left:35px;bottom:194px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1a_249{left:35px;bottom:174px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1b_249{left:35px;bottom:155px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1c_249{left:35px;bottom:135px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1d_249{left:35px;bottom:116px;letter-spacing:0.16px;}
#t1e_249{left:405px;bottom:116px;}
#t1f_249{left:618px;bottom:777px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1g_249{left:618px;bottom:759px;}
#t1h_249{left:618px;bottom:739px;letter-spacing:0.2px;}
#t1i_249{left:662px;bottom:739px;}
#t1j_249{left:618px;bottom:702px;letter-spacing:0.14px;word-spacing:-0.14px;}
#t1k_249{left:618px;bottom:683px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1l_249{left:618px;bottom:665px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1m_249{left:618px;bottom:645px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t1n_249{left:715px;bottom:645px;letter-spacing:0.16px;}
#t1o_249{left:1084px;bottom:645px;}
#t1p_249{left:618px;bottom:608px;letter-spacing:0.08px;word-spacing:-0.21px;}
#t1q_249{left:618px;bottom:589px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1r_249{left:618px;bottom:570px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1s_249{left:618px;bottom:551px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1t_249{left:618px;bottom:531px;letter-spacing:0.16px;}
#t1u_249{left:988px;bottom:531px;}
#t1v_249{left:618px;bottom:495px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1w_249{left:618px;bottom:476px;letter-spacing:0.03px;word-spacing:-0.93px;}
#t1x_249{left:618px;bottom:457px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1y_249{left:618px;bottom:437px;letter-spacing:0.16px;}
#t1z_249{left:988px;bottom:437px;}
#t20_249{left:618px;bottom:401px;letter-spacing:0.06px;word-spacing:0.13px;}
#t21_249{left:618px;bottom:382px;letter-spacing:0.11px;word-spacing:0.07px;}
#t22_249{left:618px;bottom:363px;letter-spacing:0.05px;word-spacing:-0.55px;}
#t23_249{left:618px;bottom:343px;letter-spacing:0.08px;word-spacing:0.1px;}
#t24_249{left:618px;bottom:324px;letter-spacing:0.06px;word-spacing:0.12px;}
#t25_249{left:618px;bottom:304px;letter-spacing:0.16px;}
#t26_249{left:988px;bottom:304px;}
#t27_249{left:618px;bottom:269px;letter-spacing:0.07px;word-spacing:0.11px;}
#t28_249{left:618px;bottom:249px;letter-spacing:0.09px;word-spacing:0.1px;}
#t29_249{left:618px;bottom:229px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2a_249{left:618px;bottom:210px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t2b_249{left:715px;bottom:210px;letter-spacing:0.16px;}
#t2c_249{left:1084px;bottom:210px;}
#t2d_249{left:618px;bottom:174px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2e_249{left:618px;bottom:155px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2f_249{left:618px;bottom:135px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2g_249{left:618px;bottom:116px;letter-spacing:0.06px;word-spacing:0.12px;}
#t2h_249{left:618px;bottom:96px;letter-spacing:0.16px;}
#t2i_249{left:988px;bottom:96px;}
#t2j_249{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_249{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_249{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_249{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_249{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_249{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_249{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_249{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts249" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg249Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg249" style="-webkit-user-select: none;"><object width="1210" height="935" data="249/249.svg" type="image/svg+xml" id="pdf249" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_249" class="t s0_249">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_249" class="t s1_249">© </span>
<span id="t3_249" class="t s0_249">(NCCN </span>
<span id="t4_249" class="t s1_249">© </span>
<span id="t5_249" class="t s0_249">), All rights reserved. NCCN Guidelines </span>
<span id="t6_249" class="t s1_249">® </span>
<span id="t7_249" class="t s0_249">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_249" class="t s2_249">NCCN Guidelines Version 4.2024 </span>
<span id="t9_249" class="t s2_249">Head and Neck Cancers </span>
<span id="ta_249" class="t s3_249">MS-108 </span>
<span id="tb_249" class="t s4_249">664. Romesser PB, Cahlon O, Scher ED, et al. Proton beam reirradiation </span>
<span id="tc_249" class="t s4_249">for recurrent head and neck cancer: multi-institutional report on feasibility </span>
<span id="td_249" class="t s4_249">and early outcomes. Int J Radiat Oncol Biol Phys 2016;95:386-395. </span>
<span id="te_249" class="t s4_249">Available at: </span><span id="tf_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/27084656</span><span id="tg_249" class="t s4_249">. </span>
<span id="th_249" class="t s4_249">665. Verma V, Rwigema JM, Malyapa RS, et al. Systematic assessment </span>
<span id="ti_249" class="t s4_249">of clinical outcomes and toxicities of proton radiotherapy for reirradiation. </span>
<span id="tj_249" class="t s4_249">Radiother Oncol 2017;125:21-30. Available at: </span>
<span id="tk_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/28941560</span><span id="tl_249" class="t s4_249">. </span>
<span id="tm_249" class="t s4_249">666. Caudell JJ, Ward MC, Riaz N, et al. Volume, dose, and fractionation </span>
<span id="tn_249" class="t s4_249">considerations for IMRT-based reirradiation in head and neck cancer: a </span>
<span id="to_249" class="t s4_249">multi-institution analysis. Int J Radiat Oncol Biol Phys 2018;100:606-617. </span>
<span id="tp_249" class="t s4_249">Available at: </span><span id="tq_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/29413274</span><span id="tr_249" class="t s4_249">. </span>
<span id="ts_249" class="t s4_249">667. Prescribing Information for nivolumab; 2022. Available at: </span>
<span id="tt_249" class="t s5_249">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s112l </span>
<span id="tu_249" class="t s5_249">bl.pdf </span><span id="tv_249" class="t s4_249">. </span>
<span id="tw_249" class="t s4_249">668. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of </span>
<span id="tx_249" class="t s4_249">pembrolizumab for treatment of recurrent or metastatic squamous cell </span>
<span id="ty_249" class="t s4_249">carcinoma of the head and neck (KEYNOTE-012): an open-label, </span>
<span id="tz_249" class="t s4_249">multicentre, phase 1b trial. Lancet Oncol 2016;17:956-965. Available at: </span>
<span id="t10_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/27247226</span><span id="t11_249" class="t s4_249">. </span>
<span id="t12_249" class="t s4_249">669. Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of </span>
<span id="t13_249" class="t s4_249">pembrolizumab in biomarker-unselected patients with recurrent and/or </span>
<span id="t14_249" class="t s4_249">metastatic head and neck squamous cell carcinoma: results from the </span>
<span id="t15_249" class="t s4_249">phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34:3838- </span>
<span id="t16_249" class="t s4_249">3845. Available at: </span><span id="t17_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/27646946</span><span id="t18_249" class="t s4_249">. </span>
<span id="t19_249" class="t s4_249">670. Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of </span>
<span id="t1a_249" class="t s4_249">pembrolizumab in recurrent/metastatic head and neck squamous cell </span>
<span id="t1b_249" class="t s4_249">carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. </span>
<span id="t1c_249" class="t s4_249">Br J Cancer 2018;119:153-159. Available at: </span>
<span id="t1d_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/29955135</span><span id="t1e_249" class="t s4_249">. </span>
<span id="t1f_249" class="t s4_249">671. Prescribing Information for pembrolizumab; 2022. Available at: </span>
<span id="t1g_249" class="t s5_249">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110l </span>
<span id="t1h_249" class="t s5_249">bl.pdf </span><span id="t1i_249" class="t s4_249">. </span>
<span id="t1j_249" class="t s4_249">672. Harrington KJ, Soulieres D, Le Tourneau C, et al. Quality of life with </span>
<span id="t1k_249" class="t s4_249">pembrolizumab for recurrent and/or metastatic head and neck squamous </span>
<span id="t1l_249" class="t s4_249">cell carcinoma: KEYNOTE-040. J Natl Cancer Inst 2021;113:171-181. </span>
<span id="t1m_249" class="t s4_249">Available at: </span><span id="t1n_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/32407532</span><span id="t1o_249" class="t s4_249">. </span>
<span id="t1p_249" class="t s4_249">673. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in </span>
<span id="t1q_249" class="t s4_249">patients with noncolorectal high microsatellite instability/mismatch repair- </span>
<span id="t1r_249" class="t s4_249">deficient cancer: results from the phase II KEYNOTE-158 study. J Clin </span>
<span id="t1s_249" class="t s4_249">Oncol 2020;38:1-10. Available at: </span>
<span id="t1t_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/31682550</span><span id="t1u_249" class="t s4_249">. </span>
<span id="t1v_249" class="t s4_249">674. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- </span>
<span id="t1w_249" class="t s4_249">and cetuximab-refractory head and neck cancer: results from a single-arm, </span>
<span id="t1x_249" class="t s4_249">phase II study. J Clin Oncol 2017;35:1542-1549. Available at: </span>
<span id="t1y_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/28328302</span><span id="t1z_249" class="t s4_249">. </span>
<span id="t20_249" class="t s4_249">675. Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus </span>
<span id="t21_249" class="t s4_249">methotrexate as second-line treatment in patients with recurrent or </span>
<span id="t22_249" class="t s4_249">metastatic squamous-cell carcinoma of the head and neck progressing on </span>
<span id="t23_249" class="t s4_249">or after platinum-based therapy (LUX-Head &amp; Neck 1): an open-label, </span>
<span id="t24_249" class="t s4_249">randomised phase 3 trial. Lancet Oncol 2015;16:583-594. Available at: </span>
<span id="t25_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/25892145</span><span id="t26_249" class="t s4_249">. </span>
<span id="t27_249" class="t s4_249">676. Seiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II </span>
<span id="t28_249" class="t s4_249">study of afatinib versus cetuximab in metastatic or recurrent squamous </span>
<span id="t29_249" class="t s4_249">cell carcinoma of the head and neck. Ann Oncol 2014;25:1813-1820. </span>
<span id="t2a_249" class="t s4_249">Available at: </span><span id="t2b_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/24928832</span><span id="t2c_249" class="t s4_249">. </span>
<span id="t2d_249" class="t s4_249">677. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of </span>
<span id="t2e_249" class="t s4_249">trastuzumab deruxtecan in patients with HER2-expressing solid tumors: </span>
<span id="t2f_249" class="t s4_249">primary results from the Destiny-PanTumor02 phase II trial. J Clin Oncol </span>
<span id="t2g_249" class="t s4_249">2024;42:47-58. Available at: </span>
<span id="t2h_249" class="t s5_249">https://www.ncbi.nlm.nih.gov/pubmed/37870536</span><span id="t2i_249" class="t s4_249">. </span>
<span id="t2j_249" class="t s6_249">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
